Safety of Resuming Tumor Necrosis Factor Inhibitors in Ankylosing ...

Median time to resuming TNF inhibitor from tuberculosis was 3.3 and 9.0 months in the early and late resumers, respectively. Tuberculosis was ...

Conclusions: Instances of tuberculosis were treated successfully in our AS patients, even when given concomitantly with TNF inhibitors. We suggest that early ...

FRI0401 Safety of Resuming Tumor Necrosis Factor Inhibitors in ...

Fifteen patients resumed TNF inhibitors during anti-tuberculosis treatment (early resumers) and 8 after completion of TI treatment (late resumers). Median time ...

Safety of resuming tumor necrosis factor inhibitors in ankylosing ...

Safety of resuming tumor necrosis factor inhibitors in ankylosing spondylitis patients concomitant with the treatment of active tuberculosis: A ...

Safety of Resuming Tumor Necrosis Factor Inhibitors in Ankylosing ...

Conclusions Instances of tuberculosis were treated successfully in our AS patients, even when given concomitantly with TNF inhibitors. We ...

FRI0401 Safety of Resuming Tumor Necrosis Factor Inhibitors in ...

FRI0401 Safety of Resuming Tumor Necrosis Factor Inhibitors in Ankylosing Spondylitis Patients Concomitant with The Treatment of Active Tuberculosis: A ...

Safety of Resuming Tumor Necrosis Factor Inhibitors in Ankylosing ...

« Back to Article. Fig 1. Flow diagram of patient selection. AS, ankylosing spondylitis; TB, tuberculosis; TNF, tumor necrosis factor.

Safety of resuming tumour necrosis factor inhibitors in patients who ...

Objectives. There is no consensus on whether restarting TNF inhibitors (TNFis) after treatment of an active tuberculosis (TB) infection caused ...

The Safety Profile of Tumor Necrosis Factor Inhibitors in Ankylosing ...

Tumor necrosis factor (TNF) inhibitors significantly improved the treatment options for patients with ankylosing spondylitis. Unfortunately, currently ...

Safety Of Resuming The Tumor Necrosis Factor Antagonists ...

Conclusion: Active tuberculosis infection in relation to TNF antagonist may be safe for resuming the therapy even before completion of TI treatment. Our results ...

Safe Re-administration of Tumor Necrosis Factor-alpha (TNFα ...

All patients discontinued TNFα inhibitors with starting the treatment of TB. Eight patients were re-administered TNFα inhibitors due to disease ...

Safety of Resuming Tumor Necrosis Factor Inhibitors in Ankylosing ...

Safety of Resuming Tumor Necrosis Factor Inhibitors in Ankylosing Spondylitis Patients Concomitant with the Treatment of Active Tuberculosis: A ...

Safety of tumor necrosis factor inhibitor use in patients with ...

Safety for tumor necrosis factor inhibitors (TNFi) in cancer has been focused on risk of incident malignancies, but studies on prognostic ...

Safety of Resuming Tumor Necrosis Factor Inhibitors in Ankylosing ...

Please send documents regarding finances to the ASAS-treasurer. Floris van Gaalen. Dept. of Rheumatology, C-01-038. Postbus 9600, ...

Adverse events of tumor necrosis factor alpha inhibitors for the ...

Conclusion: The available data indicated that ankylosing spondylitis patients who received tumor necrosis factor alpha inhibitors had no ...

Efficacy and safety of anti-TNF therapy for ankylosing spondylitis

Several studies have shown that tumor necrosis factor (TNF)-blockers are safe and effective short-term treatments for ankylosing spondylitis. Two open-label ...

Safe Re-administration of Tumor Necrosis Factor-alpha (TNFα ...

TNFα inhibitors could be safely resumed after starting anti-TB regimen in patients with RA or AS. Keywords: TNFα Inhibitor; Tuberculosis; Arthritis, Rheumatoid; ...

Safety of Resuming Tumor Necrosis Factor Inhibitors in Ankylosing ...

Safety of Resuming Tumor Necrosis Factor Inhibitors in Ankylosing Spondylitis Patients Concomitant with the Treatment of Active Tuberculosis: A ...

Safety of Resuming Tumor Necrosis Factor Inhibitors in Ankylosing ...

Patients who develop an active tuberculosis infection during tumor necrosis factor (TNF) inhibitor treatment typically discontinue TNF inhibitor and receive ...

Assessing safety and efficacy of TNFi treatment in late onset ... - Nature

Clinical data on the use of tumour necrosis factor inhibitors (TNFi) in late-onset ankylosing spondylitis (LoAS) are limited.